Entelos, Novartis agree to research collaboration using PhysioLab platforms, virtual patients

By Lisa Kerner

Charlotte, N.C., Aug. 22 - Entelos, Inc. and Novartis Pharma AG have agreed to collaborate on research projects in multiple disease areas. Financial terms were not disclosed.

Novartis will provide research and development funding under the agreement.

Entelos will conduct biosimulation research using its PhysioLab platforms designed to predict the effects of drugs using "virtual patients," according to a company news release.

Novartis is a Basel, Switzerland, pharmaceutical company.

Based in Foster City, Calif., Entelos is a life-sciences company that creates computer models of human physiology used in drug discovery and development.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.